https://scholars.lib.ntu.edu.tw/handle/123456789/558573
標題: | Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group | 作者: | Andr? T. Vernerey D. Im S.A. Bodoky G. Buzzoni R. Reingold S. Rivera F. McKendrick J. Scheithauer W. Ravit G. Fountzilas G. Yong W.P. Isaacs R. ?sterlund P. JIN-TUNG LIANG Creemers G.J. Rakez M. Van Cutsem E. Cunningham D. Tabernero J. de Gramont A. |
關鍵字: | adjuvant; bevacizumab; colon cancer; FOLFOX; XELOX | 公開日期: | 2020 | 出版社: | Elsevier Ltd | 卷: | 31 | 期: | 2 | 起(迄)頁: | 246-256 | 來源出版物: | Annals of Oncology | 摘要: | Background: The bevacizumab-Avastin? adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here the long-term survival results (S-AVANT). Patients and methods: Patients with curatively resected stage III CC were randomly assigned to FOLFOX4, FOLFOX4-bevacizumab, or XELOX-bevacizumab. Results: A total of 2867 patients were randomized: FOLFOX4: n = 955, FOLFOX4-bevacizumab: n = 960, XELOX-bevacizumab: n = 952. With a median of 6.73 years follow-up (interquartile range 5.51–10.54), 672 patients died, of whom 198 (20.7%), 250 (26.0%), and 224 (23.5%) were in the FOLFOX4, FOLFOX4-bevacizumab, and XELOX-bevacizumab arms, respectively. The 10-year overall survival (OS) rates were 74.6%, 67.2%, and 69.9%, (P = 0.003) and 5-year disease-free survival (DFS) rates were 73.2%, 68.5%, and 71.0% (P = 0.174), respectively. OS and DFS hazard ratios were 1.29 [95% confidence interval (CI) 1.07–1.55; P = 0.008] and 1.16 (95% CI 0.99–1.37; P = 0.063) for FOLFOX4-bevacizumab versus FOLFOX4 and 1.15 (95% CI 0.95–1.39; P = 0.147) and 1.1 (95% CI 0.93–1.29; P = 0.269) for XELOX-bevacizumab versus FOLFOX4, respectively. CC-related deaths (n = 542) occurred in 157 (79.3%) patients receiving FOLFOX4, 205 (82.0%) receiving FOLFOX4-bevacizumab, and 180 (80.4%) receiving XELOX-bevacizumab (P = 0.764), while non-CC-related deaths occurred in 41 (20.7%), 45 (18.0%), and 44 (19.6%) patients, respectively. Cardiovascular-related and sudden deaths during treatment or follow-up were reported in 13 (6.6%), 17 (6.8%), and 14 (6.3%) patients, in the FOLFOX4, FOLFOX4-bevacizuamb, and XELOX-bevacizumab arms, respectively (P = 0.789). Treatment arm, sex, age, histological differentiation, performance status, T/ N stages, and localization of primary tumor were independent prognostic factors of OS in stage III. Conclusions: S-AVANT confirms the initial AVANT report. No benefit of the bevacizumab addition to FOLFOX4 adjuvant therapy in patients with stage III CC was observed in terms of DFS with a negative effect in OS, without increase in non-CC related deaths. Clinical trial identification: NCT00112918. ? 2019 European Society for Medical Oncology |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078554434&doi=10.1016%2fj.annonc.2019.12.006&partnerID=40&md5=73065e78804e9a990cfe096abfdc2bd5 https://scholars.lib.ntu.edu.tw/handle/123456789/558573 |
ISSN: | 0923-7534 | DOI: | 10.1016/j.annonc.2019.12.006 | SDG/關鍵字: | bevacizumab; capecitabine; fluorouracil; folinic acid; oxaliplatin; antineoplastic agent; bevacizumab; fluorouracil; folinic acid; platinum complex; adult; aged; Article; cancer adjuvant therapy; cancer grading; cancer prognosis; cancer staging; cancer survival; colon cancer; colorectal cancer; comorbidity; controlled study; disease free survival; drug withdrawal; female; hazard ratio; human; long term care; major clinical study; male; monotherapy; overall survival; phase 3 clinical trial; primary tumor; priority journal; randomized controlled trial; sudden death; toxicity; treatment planning; adjuvant chemotherapy; clinical trial; colon tumor; pathology; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。